Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial.
Toby M MaherR Gisli JenkinsVincent CottinYasuhiko NishiokaImre NothMoisés SelmanJin Woo SongCarina IttrichClaudia DiefenbachSusanne StowasserEric S WhitePublished in: ERJ open research (2024)
Among subjects with IPF and preserved FVC, multivariate models based on demographic/clinical characteristics and biomarker levels at baseline did not provide an accurate prediction of which patients would progress.
Keyphrases
- idiopathic pulmonary fibrosis
- end stage renal disease
- interstitial lung disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- electronic health record
- study protocol
- data analysis
- patient reported outcomes
- machine learning
- open label
- mass spectrometry
- systemic sclerosis
- deep learning